Independent.ie8h
Ask the doctor: I have a strange growth on my eyelid – should I be concerned?
Question: I recently noticed a strange growth on my bottom eyelid. It isn’t coming out of a hair follicle, and it isn’t a ...
Lung cancer rising among non-smokers — here's why
The most common form of lung cancer is primarily found in non-smokers, a new study reveals. Doctors react to the surprising ...
Targeted Oncology16h
FDA Fast-Tracks IBI363 in Squamous NSCLC
The FDA granted fast track status to IBI363 for the treatment of patients with advanced squamous lung cancer after prior ...
The Pharma Letter17h
Purple Biotech advances NT219 into Phase II head and neck cancer study
Israel-based clinical-stage company Purple Biotech today announced it is advancing into a Phase II study with NT219 in ...
E!17h
Teddi Mellencamp’s Sister Shares Update After Emergency Brain Tumor Surgery
After Teddi Mellencamp underwent emergency brain surgery for her tumors, the Real Housewives of Beverly Hills star’s sister Justice Mellencamp shared an update on her recovery.
High-cost sickle cell gene therapies push insurers and Medicaid programs to find new payment models
The high cost of sickle cell gene therapies is pushing private insurers and Medicaid programs to develop new payment models.
Petosemtamab granted Breakthrough Therapy designation by the U.S. FDA for 1L PD-L1 positive head and neck squamous cell carcinoma
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company ...
Merus’ petosemtamab granted Breakthrough Therapy designation by FDA
Merus (MRUS) announced that the FDA has granted Breakthrough Therapy designation to petosemtamab in combination with pembrolizumab for the ...
Purple Biotech Ltd.: Purple Biotech Advances NT219 into Phase 2 Head and Neck Cancer Trial
NT219, a novel agent designed to overcome tumor resistance to drug therapy, will be evaluated in combination with the standard-of-care head and neck cancer drugs pembrolizumab (Keytruda) or cetuximab ...
Purple Biotech Advances NT219 into Phase 2 Head and Neck Cancer Trial
NT219, a novel agent designed to overcome tumor resistance to drug therapy, will be evaluated in combination with the ...